MCID: PSR002
MIFTS: 65

Psoriasis

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Psoriasis

MalaCards integrated aliases for Psoriasis:

Name: Psoriasis 11 19 75 28 53 5 41 2 14 63 16 71 31 33

Classifications:



External Ids:

Disease Ontology 11 DOID:8893
MeSH 43 D011565
NCIt 49 C3346
SNOMED-CT 68 156369008
ICD10 31 L40 L40.9
UMLS 71 C0033860

Summaries for Psoriasis

MedlinePlus: 41 Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast. Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include: Infections Stress Dry skin Certain medicines Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary: Psoriasis is related to psoriasis 7 and psoriasis 10, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Psoriasis is MIR203A (MicroRNA 203a), and among its related pathways/superpathways are miRNAs involvement in the immune response in sepsis and Cell differentiation - expanded index. The drugs Infliximab and Tazarotene have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and liver.

PubMed Health : 63 Psoriasis: Psoriasis is a non-contagious inflammatory disease. The main symptoms are reddish, scaly patches of skin that may itch. It is a chronic condition that is typically associated with periods of more severe skin problems (flare-ups) followed by periods of milder skin problems or none at all. Various treatments can relieve the symptoms, but there is no cure for psoriasis. Its severity can vary quite a lot. In some people it is bothersome more than anything else, and they can cope with it quite well. Others feel that it has a major effect on their quality of life, since the treatment and skin care can take a long time. Many people are also unhappy about having visible reddened and scaly skin patches – especially if they are on exposed areas of their body. Sometimes the inflammation that is causing the psoriasis affects other parts of the body too, such as the joints or nails.

GARD: 19 Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. The skin on the elbows, knees, scalp, back, face, palms and feet is most often affected, but other parts of the body can be affected as well. A problem with the immune system causes Psoriasis. In a process called cell turnover, skin cells that grow deep in the skin rise to the surface. Normally, this takes a month. In Psoriasis, it happens in just days because the cells rise too fast. Although symptoms may come and go, for many, Psoriasis is a lifelong condition. Infections, stress, dry skin and certain medications may make symptoms worse. Psoriasis usually occurs in adults. It sometimes runs in families.

CDC: 2 Psoriasis is a chronic autoimmune skin disease that speeds up the growth cycle of skin cells.

Disease Ontology: 11 A skin disease that is characterized by patches of thick red skin and silvery scales.

Wikipedia: 75 Psoriasis is a long-lasting, noncontagious autoimmune disease characterized by raised areas of abnormal... more...

Related Diseases for Psoriasis

Diseases in the Psoriasis family:

Psoriasis 1 Psoriasis 3
Psoriasis 2 Psoriasis 4
Psoriasis 5 Psoriasis 6
Psoriasis 7 Psoriasis 9
Psoriasis 8 Psoriasis 10
Psoriasis 11 Psoriasis 12
Psoriasis 13 Psoriasis 15

Diseases related to Psoriasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1572)
# Related Disease Score Top Affiliating Genes
1 psoriasis 7 33.7 PSORS7 PSORS1C3
2 psoriasis 10 33.0 PSORS1C3 PSORS10
3 psoriasis 8 33.0 PSORS8 PSORS1C3
4 psoriasis 9 32.9 PSORS9 PSORS1C3
5 skin disease 32.1 MIR31 MIR21 MIR20A MIR203A MIR17 MIR146A
6 crohn's disease 31.4 MIR31 MIR21 MIR142
7 non-alcoholic fatty liver disease 31.2 MIR31 MIR21 MIR203A MIR200A MIR17
8 cardiovascular system disease 31.2 MIR21 MIR17 MIR146B MIR146A MIR142
9 periodontitis 30.9 MIR21 MIR17 MIR142
10 cerebrovascular disease 30.9 MIR21 MIR17 MIR146A MIR142
11 immune deficiency disease 30.8 MIR31 MIR21 MIR20A MIR17 MIR146B MIR146A
12 disease of mental health 30.8 MIR21 MIR17 MIR146A MIR142
13 multiple sclerosis 30.6 MIR21 MIR20A MIR17 MIR146A MIR142
14 arteries, anomalies of 30.6 MIR21 MIR20A MIR17 MIR146B MIR146A MIR142
15 bone inflammation disease 30.6 MIR21 MIR17 MIR146A MIR142
16 body mass index quantitative trait locus 11 30.6 MIR21 MIR20A MIR17 MIR146B MIR146A MIR142
17 respiratory failure 30.5 MIR21 MIR17 MIR146A MIR142
18 demyelinating disease 30.4 MIR21 MIR146A MIR142
19 gastrointestinal system disease 30.3 MIR31 MIR21 MIR20A MIR200A MIR17 MIR146B
20 heart valve disease 30.3 MIR21 MIR17 MIR146A MIR142
21 kidney cancer 30.3 MIR21 MIR20A MIR17 MIR142
22 connective tissue disease 30.2 MIR31 MIR21 MIR20A MIR200A MIR17 MIR146B
23 lymphoma, non-hodgkin, familial 30.2 MIR31 MIR21 MIR20A MIR200A MIR17 MIR146B
24 larynx cancer 30.2 MIR31 MIR21 MIR17 MIR142
25 eye disease 30.2 MIR21 MIR20A MIR200A MIR17 MIR146B MIR146A
26 hematologic cancer 30.2 MIR31 MIR21 MIR20A MIR17 MIR146B MIR146A
27 peripheral nervous system disease 30.2 MIR31 MIR21 MIR17 MIR146A MIR142
28 leukemia, acute myeloid 30.2 MIR31 MIR21 MIR17 MIR146A MIR142
29 retinal vascular disease 30.1 MIR21 MIR20A MIR17 MIR146B
30 human papillomavirus infectious disease 30.1 MIR31 MIR21 MIR142
31 microvascular complications of diabetes 5 30.1 MIR21 MIR20A MIR17 MIR146B
32 bone disease 30.1 MIR21 MIR17 MIR146A MIR142
33 renal cell carcinoma, nonpapillary 30.1 MIR31 MIR21 MIR20A MIR200A MIR17 MIR146B
34 intermediate coronary syndrome 30.1 MIR21 MIR17 MIR142
35 lipid storage disease 30.1 MIR21 MIR17 MIR142
36 lung cancer susceptibility 3 30.1 MIR31 MIR21 MIR200A MIR17 MIR142
37 mouth disease 30.0 MIR31 MIR21 MIR17 MIR142
38 leukemia, chronic lymphocytic 30.0 MIR31 MIR21 MIR20A MIR17 MIR146B MIR146A
39 pharynx cancer 29.9 MIR31 MIR21 MIR17 MIR146A MIR142
40 spinal disease 29.8 MIR31 MIR21 MIR20A MIR200A MIR17 MIR146B
41 oral squamous cell carcinoma 29.8 MIR31 MIR21 MIR203A MIR200A MIR17 MIR146A
42 biliary tract disease 29.8 MIR31 MIR21 MIR17 MIR142
43 nasopharyngeal carcinoma 29.8 MIR31 MIR21 MIR17 MIR146A MIR142
44 carbohydrate metabolic disorder 29.8 MIR21 MIR20A MIR200A MIR17 MIR146B MIR146A
45 rectal benign neoplasm 29.8 MIR31 MIR20A MIR17
46 rectum cancer 29.7 MIR31 MIR21 MIR20A MIR200A MIR17 MIR142
47 intestinal disease 29.7 MIR31 MIR21 MIR20A MIR200A MIR17 MIR146B
48 head and neck cancer 29.6 MIR31 MIR21 MIR20A MIR200A MIR17 MIR146B
49 retinal disease 29.6 MIR21 MIR20A MIR17 MIR146B MIR146A MIR142
50 lymphatic system disease 29.5 MIR31 MIR21 MIR20A MIR17 MIR146B MIR146A

Graphical network of the top 20 diseases related to Psoriasis:



Diseases related to Psoriasis

Symptoms & Phenotypes for Psoriasis

UMLS symptoms related to Psoriasis:


pruritus; exanthema; psoriasiform rash

Drugs & Therapeutics for Psoriasis

PubMed Health treatment related to Psoriasis: 63

There are various treatment options for psoriasis: Basic therapy (skin care) : Care of the affected areas of skin using lipid -replenishing ointments, creams or lotions. This is done to keep the skin supple, protect it from injury and relieve itching . Some products also contain medications that are supposed to reduce shedding, such as urea or salicylic acid . Topical treatment : Products containing corticosteroids or vitamin D analogues are typically used in topical treatment (treatment applied to the skin from the outside). These are available in the form of creams, ointments lotions or foams. Light therapy : Light therapy, also known as phototherapy, involves exposing the plaques to ultraviolet light (UV light ). The UV light reduces inflammation in the skin , and also slows the production of cells . Sometimes medications called psoralens are used in combination with light therapy. Psoralens make the skin more sensitive to light. Light therapy is best suited for people who have moderate or severe psoriasis and in whom topical treatment alone wasn't effective enough. Medications that are taken orally or injected : These medicines are a treatment option for moderate or severe psoriasis. They inhibit the body's immune response. Methotrexate (MTX), fumaric acid esters, apremilast and biological drugs (biologics) are commonly used for this purpose. Basic moisturizing skin care is always recommended for psoriasis – during periods without any skin problems, too. There are also many herbal medicines for the treatment of psoriasis, including extracts of barberry (Mahonia aquifolium), birch bark or aloe vera. The effectiveness of these herbal medicines hasn't been tested in any good-quality studies, though. So it isn't known whether they can help. Some studies suggest that people with psoriasis who are overweight can improve the condition of their skin by losing a few pounds. It is sometimes claimed that a tonsillectomy (removal of the tonsils ) can relieve psoriasis symptoms , but there hasn't been much research in this area. Tonsillectomy usually isn't recommended because the operation may cause complications such as infections, bleeding and changes to the person's voice . There are also no studies showing that having your tonsils out can cure or prevent psoriasis.

Drugs for Psoriasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 364)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 4 170277-31-3
2
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
3
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
4
Dapsone Approved, Investigational Phase 4 80-08-0 2955
5
Vedolizumab Approved Phase 4 943609-66-3
6
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
7
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
8
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
9
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
12
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
13
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
14
Fluticasone Approved, Experimental Phase 4 90566-53-3 4659387 5311101
15
Desoximetasone Approved Phase 4 382-67-2 5311067
16
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
17
Sorbitol Approved, Investigational Phase 4 69-65-8, 50-70-4 453 6251 5780
18
Clocortolone Approved Phase 4 34097-16-0, 4828-27-7 5311052
19
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
20
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
21
Ustekinumab Approved, Investigational Phase 4 815610-63-0
22
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
23
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
24
Ixekizumab Approved, Investigational Phase 4 1143503-69-8
25
Adalimumab Approved, Experimental Phase 4 331731-18-1
26
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
27
Calcipotriol Approved Phase 4 112965-21-6 5288783
28
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 2791 5311051 32798
29
Alefacept Approved, Investigational, Withdrawn Phase 4 222535-22-0
30
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
31
Capsaicin Approved Phase 4 404-86-4 1548943
32
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
33
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453
34
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
35
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
36
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354
37
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
38
Trichostatin A Experimental Phase 4 58880-19-6 5562 444732
39 Antiprotozoal Agents Phase 4
40 Antiparasitic Agents Phase 4
41 Antimalarials Phase 4
42 Trace Elements Phase 4
43 Calciferol Phase 4
44 Micronutrients Phase 4
45 Vasoconstrictor Agents Phase 4
46 Anti-Bacterial Agents Phase 4
47 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
48 Anesthetics Phase 4
49
Chondroitin Phase 4 9007-27-6 14389182
50 Citrate Phase 4

Interventional clinical trials:

(show top 50) (show all 1637)
# Name Status NCT ID Phase Drugs
1 Palmoplantar Psoriasis: Evaluating Efficacy and Clinical Photography With Brodalumab in Palmoplantar Psoriasis Unknown status NCT04622033 Phase 4
2 A Phase 4 Multicenter, Randomized, Placebo-controlled Study Evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients With Moderate-to-severe Scalp Psoriasis Unknown status NCT03553433 Phase 4 Apremilast 30mg;Placebo Oral Tablet
3 A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
4 Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT). Unknown status NCT03307447 Phase 4 Secukinumab
5 The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
6 Open Label Study, Evaluating Taltz in Combination With Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam in Psoriasis Patients Unknown status NCT04372277 Phase 4 Enstilar
7 An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab Unknown status NCT03827876 Phase 4 Enstilar 0.005%-0.064% Topical Foam
8 A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis. Unknown status NCT04347473 Phase 4 Ilumya Injectable Product
9 Open Label Study Evaluating DUOBRII in Psoriasis Patients Being Treated With Biologic Agents. Unknown status NCT04119102 Phase 4 Duobrii
10 Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis After Combination Treatment of Lexette and Sorilux for 2 Weeks Unknown status NCT04571151 Phase 4 LEXETTE 0.05% Topical Foam;Sorilux 0.005 % Topical Foam
11 Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
12 Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
13 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
14 A Randomized Controlled Trial Comparing the Efficacy and Safety Profile of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis Unknown status NCT03408756 Phase 4 methotrexate
15 Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism: A Double-Blind, Randomized, Placebo-Controlled Study Unknown status NCT03629639 Phase 4 Metformin
16 Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis Unknown status NCT02829424 Phase 4 Methotrexate;Methotrexate Placebo
17 A Single Center Study to Evaluate the Effectiveness and Safety of Add on Enstilar® in Patients Using OTEZLA® for Moderate to Severe Plaque Psoriasis Unknown status NCT03587194 Phase 4 Otezla
18 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
19 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
20 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
21 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
22 Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis Unknown status NCT03453190 Phase 4
23 Prevalence, Pattern and Disease Course og Arthritis and Enthesitis in Patients With Psoriasis, and Effect of Apremilast in Subclinical, US-defined Psoriatic Arthritis - a Population Based Study Applying Clinical, Ultrasonic, MRI and Patient-reported Outcomes Unknown status NCT04515732 Phase 4 Apremilast Oral Tablet
24 Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis Unknown status NCT03478280 Phase 4 Brodalumab;Placebos
25 A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
26 Studying the Effect of Methotrexate Alone Versus Methotrexate and Vitamin D on the Cardiovascular Risk of Psoriatic Patients Unknown status NCT03904680 Phase 4 Methotrexate;Vitamin D
27 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
28 The Maintenance Effect of Enstilar Foam in Combination With Otezla Unknown status NCT04555707 Phase 4 Apremilast 30mg;calcipotriene and betamethasone dipropionate
29 Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions Unknown status NCT03629379 Phase 4 Ustekinumab;Vedolizumab
30 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
31 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
32 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
33 An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma Completed NCT04183881 Phase 4 Brodalumab 210mg SC
34 Evaluation of Nail Psoriasis Severity Index (NAPSI) and Modified Napsi in Patients With Nail Psoriasis Treated With Acitretin Completed NCT00723437 Phase 4 acitretin
35 Comparison of the Performance of Subjective or Objective Psoriasis Severity Assessment Tools for the Assessment of the Improvement of Psoriasis After Oral Cyclosporine A or Methotrexate Treatment Completed NCT02655705 Phase 4 Cyclosporine A;Methotrexate
36 Randomised, Open-label Preliminary Study to Assess the Effects of 2 Regimens of Etanercept on Nail and Skin Symptoms in Patients With Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept
37 A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis Completed NCT03942042 Phase 4 Ixekizumab
38 A Single-Center, Open-Label Study to Assess Change in Psychosocial and Occupational Dimensions With Ustekinumab Treatment of Moderate-to-Severe Psoriasis Evaluated With the Psychological General Well Being (PGWB), Work Productivity and Activity Impairment (WPAI), Psoriasis Quality of Life-12 Items (PQOL-12), and Dermatology Life Quality Index (DLQI) Completed NCT01511315 Phase 4 Ustekinumab
39 A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept
40 Investigator-Initiated, Open Label Trial of a Combination of Halobetasol Propionate 0.01% Andtazarotene 0.045% Lotion (Duobrii®) for Plaque Type Psoriasis of the Hands and/or Feet Completed NCT04720105 Phase 4 Duobrii®
41 An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis Completed NCT03022617 Phase 4 Apremilast
42 A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Completed NCT00287118 Phase 4 Efalizumab
43 A Double-blinded, Placebo-controlled Study to Evaluate the Tolerability and Efficacy of Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color Completed NCT03506477 Phase 4 Enstilar® foam;Vehicle foam
44 Energy-restricted, n-3 Polysaturated Fatty Acids-rich Diet Improves the Clinical Response to Immuno-modulating Drugs in Obese Patients With Plaque-type Psoriasis: a Randomized Control Clinical Trial. Completed NCT01876875 Phase 4
45 Fase IV Clinical Trial to Evaluate Chondroitin Sulphate Efficacy and Safety in Patients With Knee Osteoarthritis and Psoriasis Completed NCT00669123 Phase 4 Chondroitin sulphate;Placebo
46 Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis Completed NCT00655564 Phase 4 Alefacept
47 An Open-Label, Randomised, Phase IV Study, to Assess the Efficacy and Safety of Tildrakizumab in Patients With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy (TRANSITION) Completed NCT04263610 Phase 4 Dimethyl fumarate (DMF) standard scheme;Dimethyl fumarate (DMF) simplified scheme;Tildrakizumab
48 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Secukinumab on Aortic Vascular Inflammation and Cardiometabolic Biomarkers After 12 Weeks of Treatment, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completed NCT02690701 Phase 4 Secukinumab 300 mg
49 A Study to Evaluate the Efficacy and Tolerability of Clobetasol Propionate vs. Vehicle in the Treatment of Mild to Moderate Plaque-Type Psoriasis Completed NCT00842153 Phase 4 Clobetasol propionate foam;Vehicle foam
50 Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris Completed NCT01707043 Phase 4 Taclonex

Search NIH Clinical Center for Psoriasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acitretin
alefacept
Aloe vera preparation
Anthralin
ANTHRALIN PWDR
Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
calcipotriene
Calcitriol
Cholecalciferol
Coal Tar
Coal tar extract
Coal tar pitch volatiles
COAL TAR,COLLOIDAL
COAL TAR,REFINED
Cod Liver Oil
Colloid sulfur
Cyclosporine
Etretinate
Fish Liver Oils
fluocinolone
Fluocinolone Acetonide
hydroxyurea
Methotrexate
Methotrexate Sodium
Methoxsalen
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Salicylic Acid
SALICYLIC ACID PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
tazarotene
Thioguanine
Trioxsalen

Genetic Tests for Psoriasis

Genetic tests related to Psoriasis:

# Genetic test Affiliating Genes
1 Psoriasis 28

Anatomical Context for Psoriasis

Organs/tissues related to Psoriasis:

MalaCards : Skin, T Cells, Liver, Endothelial, Neutrophil, Monocytes, Pituitary

Publications for Psoriasis

Articles related to Psoriasis:

(show top 50) (show all 30490)
# Title Authors PMID Year
1
Liangxue Jiedu Runzhi ointment in the treatment of mild and moderate psoriasis with blood-heat syndrome: A double-blind randomized controlled trial. 62 41
36397446 2022
2
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial. 62 41
35934770 2022
3
Human umbilical cord mesenchymal stem cells for psoriasis: a phase 1/2a, single-arm study. 62 41
35927231 2022
4
MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? 62 46
17622355 2007
5
Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. 53 62
20506062 2010
6
Gene therapy for psoriasis in the K14-VEGF transgenic mouse model by topical transdermal delivery of interleukin-4 using ultradeformable cationic liposome. 53 62
20527041 2010
7
Decrease in Mycobacterium tuberculosis specific immune responses in patients with untreated psoriasis living in a tuberculosis endemic area. 53 62
19609541 2010
8
Molecular dissection of psoriasis: integrating genetics and biology. 53 62
19812592 2010
9
Platelet activation in patients with psoriasis: increased plasma levels of platelet-derived microparticles and soluble P-selectin. 53 62
19962788 2010
10
Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials. 53 62
20502723 2010
11
Cellular and molecular effects of pulsed dye laser and local narrow-band UVB therapy in psoriasis. 53 62
20333742 2010
12
Molecular diagnostics of psoriasis, atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis. 53 62
19818069 2010
13
Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. 53 62
20415816 2010
14
[Production of interleukin-8 by circulating CLA+ T cells with skin tropism in patients with psoriasis and in healthy controls]. 53 62
20223157 2010
15
Sorafenib-associated remission of psoriasis in hypernephroma: case report. 53 62
20178713 2010
16
Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. 53 62
20112373 2010
17
Tumor necrosis factor-alpha-converting enzyme as a potential mediator of the influence of smoking on the response to treatment with narrowband ultraviolet B in psoriasis patients. 53 62
20070837 2010
18
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. 53 62
20050849 2010
19
Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system. 53 62
20136921 2010
20
Differential cytokine secretion of cultured bone marrow stromal cells from patients with psoriasis and healthy volunteers. 53 62
19889595 2010
21
Significance of the S100A4 protein in psoriasis. 53 62
19641515 2010
22
Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy. 53 62
20003607 2009
23
Psoriasis patients generate increased serum levels of autoantibodies to tumor necrosis factor-alpha and interferon-alpha. 53 62
19800767 2009
24
Cell-wall-deficient bacteria: a major etiological factor for psoriasis? 53 62
20137493 2009
25
The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. 53 62
19830738 2009
26
Unraveling the genetics of complex diseases: susceptibility genes for rheumatoid arthritis and psoriasis. 53 62
19446472 2009
27
AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. 53 62
19876791 2009
28
Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. 53 62
19895991 2009
29
Neuronal changes in psoriasis exacerbation. 53 62
19453808 2009
30
Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients. 53 62
19882785 2009
31
Role of corticotropin-releasing hormone and receptor in the pathogenesis of psoriasis. 53 62
19560286 2009
32
Proinflammatory cytokine production in HaCaT cells treated by eosin: implications for the topical treatment of psoriasis. 53 62
20074471 2009
33
Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. 53 62
19659473 2009
34
Amelioration of psoriasis by anti-TNF-alpha RNAi in the xenograft transplantation model. 53 62
19568223 2009
35
Alteration of tight junction proteins is an early event in psoriasis: putative involvement of proinflammatory cytokines. 53 62
19661441 2009
36
IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. 53 62
19648274 2009
37
Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. 53 62
19295614 2009
38
NGF and its receptor system: a new dimension in the pathogenesis of psoriasis and psoriatic arthritis. 53 62
19758188 2009
39
Serum interferon-gamma is a psoriasis severity and prognostic marker. 53 62
19842576 2009
40
Common polymorphisms in the interleukin-22 gene are not associated with chronic plaque psoriasis. 53 62
19469905 2009
41
Association of cytokine gene polymorphisms with psoriasis in cases from the Nile Delta of Egypt. 53 62
19784523 2009
42
Immunohistochemical expression of cyclin-dependent kinase-2 in psoriasis. 53 62
19575732 2009
43
Using 'number needed to treat' to help conceptualize the magnitude of benefit and risk of tumour necrosis factor-alpha inhibitors for patients with severe psoriasis. 53 62
19438475 2009
44
Immunopathogenesis of psoriasis and pharmacological perspectives. 53 62
19661527 2009
45
The serotonin transporter protein is expressed in psoriasis, where it may play a role in regulating apoptosis. 53 62
19263059 2009
46
Depression and quality of life in psoriasis. 53 62
19641281 2009
47
Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgaris. 53 62
18979110 2009
48
Angiogenesis drives psoriasis pathogenesis. 53 62
19563608 2009
49
Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. 53 62
19264456 2009
50
IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. 53 62
19330474 2009

Variations for Psoriasis

ClinVar genetic disease variations for Psoriasis:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 IL17RA NM_014339.7(IL17RA):c.1173C>G (p.Tyr391Ter) SNV Likely Pathogenic
1691222 GRCh37: 22:17589282-17589282
GRCh38: 22:17108392-17108392
2 LPIN2 NM_001375808.2(LPIN2):c.1159A>G (p.Lys387Glu) SNV Benign
97813 rs104895501 GRCh37: 18:2937699-2937699
GRCh38: 18:2937701-2937701

Copy number variations for Psoriasis from CNVD:

6 (show all 27)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 107130 17 1225928 31649829 Copy number CCL3L3 Psoriasis
2 107139 17 1225928 31649843 Copy number CCL3L1 Psoriasis
3 107160 17 1242109 31665953 Copy number CCL4L2 Psoriasis
4 110229 17 31562580 31665959 Copy number CCL4L1 Psoriasis
5 209406 6 2614953 31491069 Copy number MICA Psoriasis
6 211355 6 32593131 32665540 Copy number HLA-DRB5 Psoriasis
7 212281 6 3674895 32665540 Copy number HLA-DRB1 Psoriasis
8 212427 6 3795995 32719407 Copy number HLA-DQA1 Psoriasis
9 212447 6 3813334 32742444 Copy number HLA-DQB1 Psoriasis
10 230703 8 1 12700000 Copy number Psoriasis
11 241415 8 6200000 12700000 Copy number Psoriasis
12 241416 8 6200000 12700000 Copy number DEFB103A Psoriasis
13 241417 8 6200000 12700000 Copy number DEFB104A Psoriasis
14 241418 8 6200000 12700000 Copy number DEFB4A Psoriasis
15 241438 8 6200000 12700000 Gain DEFB103A Psoriasis
16 241439 8 6200000 12700000 Gain DEFB104A Psoriasis
17 241440 8 6200000 12700000 Gain DEFB105A Psoriasis
18 241441 8 6200000 12700000 Gain DEFB106A Psoriasis
19 241442 8 6200000 12700000 Gain DEFB107A Psoriasis
20 241443 8 6200000 12700000 Gain DEFB4A Psoriasis
21 241446 8 6200000 12700000 Gain SPAG11B Psoriasis
22 241447 8 6200000 12700000 High copy numbers Psoriasis
23 241468 8 6200000 12700000 Copy number DEFB4A Psoriasis
24 242595 8 7292685 7758729 Large repeat SPAG11B Psoriasis
25 242629 8 7327435 7723985 Large repeat DEFB106A Psoriasis
26 242645 8 7332652 7718770 Large repeat DEFB105A Psoriasis
27 242649 8 7340777 7710648 Large repeat DEFB107A Psoriasis

Expression for Psoriasis

LifeMap Discovery
Genes differentially expressed in tissues of Psoriasis patients vs. healthy controls: 35 (show all 41)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 S100A9 S100 calcium binding protein A9 Skin + 7.14 0.000
2 S100A7 S100 calcium binding protein A7 Skin + 7.06 0.000
3 S100A7A S100 calcium binding protein A7A Skin + 6.53 0.000
4 S100A8 S100 calcium binding protein A8 Skin + 6.48 0.000
5 SPRR2F small proline rich protein 2F Skin + 6.27 0.000
6 PI3 peptidase inhibitor 3 Skin + 6.19 0.000
7 KRT6C keratin 6C Skin + 5.98 0.000
8 SPRR2A small proline rich protein 2A Skin + 5.97 0.000
9 KRT6A keratin 6A Skin + 5.90 0.000
10 SPRR2B small proline rich protein 2B Skin + 5.41 0.000
11 KRT6B keratin 6B Skin + 5.39 0.000
12 SPRR2D small proline rich protein 2D Skin + 5.35 0.000
13 SERPINB3 serpin family B member 3 Skin + 5.23 0.000
14 GJB2 gap junction protein beta 2 Skin + 4.97 0.000
15 SPRR2C small proline rich protein 2C (pseudogene) Skin + 4.90 0.000
16 GPR15LG G protein-coupled receptor 15 ligand Skin + 4.46 0.000
17 LCE3D late cornified envelope 3D Skin + 4.42 0.000
18 SPRR1A small proline rich protein 1A Skin + 4.34 0.000
19 LCE3A late cornified envelope 3A Skin + 4.34 0.000
20 AKR1B10 aldo-keto reductase family 1 member B10 Skin + 4.33 0.000
21 SPRR1B small proline rich protein 1B Skin + 4.29 0.000
22 KRT16 keratin 16 Skin + 4.27 0.000
23 KYNU kynureninase Skin + 4.26 0.000
24 LCN2 lipocalin 2 Skin + 4.20 0.000
25 SPRR2G small proline rich protein 2G Skin + 4.12 0.000
26 LCE3E late cornified envelope 3E Skin + 4.12 0.000
27 SERPINB4 serpin family B member 4 Skin + 3.97 0.000
28 FABP5 fatty acid binding protein 5 Skin + 3.89 0.000
29 IFI27 interferon alpha inducible protein 27 Skin + 3.80 0.000
30 TCN1 transcobalamin 1 Skin + 3.73 0.000
31 FABP5P2 fatty acid binding protein 5 pseudogene 2 Skin + 3.72 0.000
32 KLK6 kallikrein related peptidase 6 Skin + 3.54 0.000
33 IL36G interleukin 36 gamma Skin + 3.50 0.000
34 DEFB103B defensin beta 103B Skin + 3.46 0.000
35 PAMR1 peptidase domain containing associated with muscle regeneration 1 Skin - 3.43 0.000
36 GJB6 gap junction protein beta 6 Skin + 3.38 0.000
37 SPRR2E small proline rich protein 2E Skin + 3.24 0.000
38 POSTN periostin Skin - 3.14 0.000
39 CD36 CD36 molecule Skin + 3.12 0.000
40 IGFL1 IGF like family member 1 Skin + 3.11 0.000
41 CACNA1H calcium voltage-gated channel subunit alpha1 H Skin - 3.11 0.000
Search GEO for disease gene expression data for Psoriasis.

Pathways for Psoriasis

GO Terms for Psoriasis

Cellular components related to Psoriasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.55 MIR31 MIR21 MIR20A MIR203A MIR200A MIR17

Biological processes related to Psoriasis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 miRNA-mediated gene silencing GO:0035195 9.86 MIR31 MIR21 MIR20A MIR203A MIR200A MIR17
2 cellular response to lipopolysaccharide GO:0071222 9.83 MIR21 MIR20A MIR17 MIR146A
3 negative regulation of inflammatory response GO:0050728 9.76 MIR31 MIR20A MIR146A MIR142
4 negative regulation of cell adhesion molecule production GO:0060354 9.54 MIR20A MIR146A
5 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.54 MIR21 MIR20A MIR146A
6 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.51 MIR20A MIR17
7 negative regulation of vascular endothelial growth factor production GO:1904046 9.5 MIR20A MIR17 MIR146A
8 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.49 MIR21 MIR17
9 positive regulation of metalloendopeptidase activity GO:1904685 9.48 MIR21 MIR17
10 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.46 MIR21 MIR20A MIR17 MIR146A
11 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.43 MIR31 MIR146A
12 negative regulation of amyloid precursor protein biosynthetic process GO:0042985 9.43 MIR17 MIR20A MIR31
13 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.4 MIR20A MIR17
14 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.02 MIR31 MIR21 MIR20A MIR17 MIR146A

Molecular functions related to Psoriasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.43 MIR31 MIR21 MIR20A MIR17 MIR146A MIR142
2 mRNA base-pairing translational repressor activity GO:1903231 9.28 MIR31 MIR21 MIR20A MIR203A MIR200A MIR17

Sources for Psoriasis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....